Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thickness, a secondary measure. The drug was well tolerated with no unexpected side effects. Oculis will not pursue FDA approval for OCS-01 for this condition but will focus on other drug candidates, including Privosegtor for optic nerve disorders and Licaminlimab for dry eye disease. The company maintains strong financial health with cash to fund operations through late 2029.
China's 15th Five-Year Plan (2026-2030) focuses on innovation, resilience, and quality growth, aiming to lead in sectors like quantum computing and 5G. Former EU economist Rudy Aernoudt highlights China's clear, unified long-term planning approach as...
Hypersurface has acquired Acre to create the Hypersurface Bitcoin Premium Income vault (HSBPI), the first fully on-chain Bitcoin volatility trading strategy. This new product allows Bitcoin holders to deposit BTC directly and earn premium income thro...
Muskrat Dam First Nation in northern Ontario was connected to the provincial power grid on April 9, 2026, allowing the community to shut down costly diesel generators. This connection removes previous power constraints, enabling new construction proj...
Zealthy has introduced an upgraded virtual weight-loss care platform that integrates telehealth services, insurance coordination, prescription management, and patient support. The platform allows eligible patients to complete an online health assessm...
EARNED, a baseball culture brand, has signed Cody Boshell, a leading 2026 MLB Draft prospect and University of Tennessee commit, as a brand ambassador. Boshell is recognized for his powerful left-handed batting and strong work ethic, aligning with EA...
